Sema + Cagri Blend

The Sema + Cagri Blend combines Semaglutide (GLP-1 receptor agonist, 5 mg) and Cagrilintide (amylin analog, 5 mg) in a single lyophilized co-formulation. This combination addresses two distinct and complementary pathways in metabolic regulation: the incretin pathway via GLP-1R and the amylin pathway via CALCR/RAMP receptors.

Clinical research on this combination (known commercially as CagriSema) has shown additive or potentially synergistic effects on weight reduction and glycemic control compared to either agent alone, making it a subject of active investigation in obesity and metabolic syndrome research.

• Dual GLP-1 and amylin receptor pathway co-activation studies
• Synergistic vs additive metabolic effect research
• Energy balance and satiety combined signaling studies
• Preclinical and clinical metabolic combination protocol models
• Comparative efficacy studies: dual vs single agonist protocols
• Body weight regulation multi-target pharmacology

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.